A Study Involving Collection of Samples and Data From Sarcoma Patients Receiving Immunotherapy

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT06113315
Status
Enrolling By Invitation

Conditions

  • Sarcoma

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Study Details

The researchers are doing this study to improve their knowledge about immunotherapy use and how effective it is as a treatment for people with sarcoma by collecting information from participants' medical records who have been treated with immune checkpoint blockade or T-cell receptor-based therapy.

Key Dates

Start date
Oct 27, 2023
Status verified
Oct 2025
Primary completion
Oct 31, 2028
Completion
Oct 31, 2028

Study Design

Enrollment
250 participants (estimated)

Arms

  • Arm: Treatment-naïve patients who have not received any ICB and/or ACT treatment at time of consent
    This is an observational prospective cohort study of patients with sarcoma treated with immune checkpoint blockade (ICB; anti-PD-1, PD-L1, and/or CTLA-4) or adoptive cell therapy (ACT; tumor infiltrating lymphocytes and/or engineered T cell receptor therapy) at Memorial Sloan Kettering Cancer Center (MSK).
  • Arm: Treatment-experienced patients who have already received ICB and/or ACT treatment at time of consent
    This is an observational prospective cohort study of patients with sarcoma treated with immune checkpoint blockade (ICB; anti-PD-1, PD-L1, and/or CTLA-4) or adoptive cell therapy (ACT; tumor infiltrating lymphocytes and/or engineered T cell receptor therapy) at Memorial Sloan Kettering Cancer Center (MSK).

Primary Outcome Measure

prospectively collect and store blood [ Time Frame: up to 5 years ]

Locations (7)

Find similar trials in Basking Ridge, NJ

Related Studies